Dr. Secemsky was a featured presenter at this year's AMP symposium in Boston, MA. Among the hot topics he presented on were new data from CLTI trials and the case for IVUS use in PAD interventions with drug-coated devices.
To learn more about Dr. Secemsky's recent related work in CLTI and PAD management, check out the following papers:
Treatment of CLTI:
Dubosq-Lebaz M, Kim J, Li S, Gouëffic Y, Sobocinski J, Secemsky E. The Impact of Medicaid Enrollment on Care Pathways and Limb Outcomes Among Patients With Chronic Limb-Threatening Ischemia. Am J Cardiol. 2026 Jun 1. PMID: 41850470.
Dubosq-Lebaz M, Li S, Gouëffic Y, Lee HH, Kim JM, Sobocinski J, Behrendt CA, Iida O, Secemsky EA. Safety and effectiveness of drug-coated devices in chronic limb-threatening ischaemia: a nationwide analysis. EuroIntervention. 2026 Mar 2. PMCID: PMC12927628.
Dangas K, Kim JM, Li S, Song Y, Chandra V, Wadhera RK, Yeh RW, Secemsky EA. Sex differences in rate and outcomes of endovascular revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2026 Jul. PMCID: PMC13022706.
IVUS in PAD:
d'Entremont MA, Secemsky EA, et al. Intravascular Ultrasound versus Angiography for Lower Extremity Peripheral Artery Disease Endovascular Revascularization: A Systematic Review and Meta-Analysis. J Vasc Surg. 2026 Aug 3. PMID: 42546858.
Revascularization strategies for PAD:
Dubosq-Lebaz M, Schneider PA, Watson NW, Brodmann M, Rundback JH, Secemsky EA. Contemporary Indications for Bioresorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: An International Expert Consensus. J Soc Cardiovasc Angiogr Interv. 2026 Jun 18. PMCID: PMC13400105.
Mufarrih SH, Qureshi NQ, Secemsky E, Kazimuddin M, Onofrey K, Giri J, Shishehbor M, Banerjee S, Aronow HD. Comparative Efficacy of Endovascular Revascularization Modalities for Symptomatic Infrapopliteal Peripheral Artery Disease: A Network Meta-Analysis. JACC Cardiovasc Interv. 2026 Jul 13. PMID: 42442894.